TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* The participants who completed the 169 days, full study period of Phase II (IM101-071) and were not administered other biologics between completion of IM101-071 and registration of this long-term study.~* The participants of the Phase I study (IM101-034), who received abatacept, except participants who were withdrawn from the study due to safety problems related to abatacept.~* New subjects with MTX intolerance: rheumatoid arthritis (RA) patients to whom MTX cannot be administered for safety reasons and who present an inadequate response to disease-modifying antirheumatic drugs (DMARDs;excluding MTX) or biologics (new subjects with MTX intolerance: RA patients who present an inadequate response to DMARDs).~Exclusion Criteria~* Women of childbearing potential (WOCBP) who were unwilling or unable to use an acceptable method of contraception.~* Participants who have received non approved or investigational biologics (other than abatacept from previous or ongoing studies in Japan) at registration.~* Participants who have received treatment with any investigational drug within 56 days before registration or five half-lives (whichever is the longest).~* Participants currently receiving treatment with leflunomide, mycophenolate mofetil, calcineurine inhibitors such as cyclosporine and tacrolimus, D-Penicillamine, Cyclophosphamide, or immunoadsorption columns.~* The participants who completed Phase II (IM101-071) are not applicable in the following instances at time of registration: with active vasculitis, symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease, breast cancer, or a history of cancer within the last 5 years, evidence of active or latent bacterial , viral infections, any serious or chronic, at risk of tuberculosis (TB), with any opportunistic infections, laboratory values of hemoglobin \< 8.5 g/dL, white blood cells (WBC) \< 3,000/mm\^3, Platelets \< 100,000/mm\^3, Serum creatinine \> 2 times upper limit of normal (ULN), Serum alanine transaminase or aspartate aminotransferase \> 2 times ULN.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Participants from Phase I study (IM101-034) (Type: EXPERIMENTAL): None
- Arm 2: Participants from Phase II study (IM101-071) (Type: EXPERIMENTAL): None
- Arm 3: New Participants with Methotrexate (MTX) Intolerance (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients of diagnosed covid-19 age \> 20years~* with or without androgenetic alopecia~* with or without comorbidities~* irrespective of disease duration -~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 100 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 13-22 years, at least two years post-menarche~* Body mass index (BMI, kg/m2) between 18 -30 kg/m2~* Surgical diagnosis of endometriosis~* Clinical decision to treat with a GnRH agonist, leuprolide depot (Lupron Depot®; TAP Pharmaceuticals, Inc.) 11.25 mg intra-muscular every 3 months~Exclusion Criteria:~* Concomitant chronic diseases which affect bone health, such as cystic fibrosis, inflammatory bowel disease, renal disease, or diabetes mellitus~* Markedly impaired liver function or liver failure~* Personal history of thromboembolic event (such as deep venous thrombosis)~* Medication use known to affect bone metabolism:~  * Glucocorticoid therapy (including inhaled steroids) or anticonvulsants used in the last 6 months

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Norethindrone acetate + estrogens (Type: EXPERIMENTAL): Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + conjugated equine estrogens 0.625 mg by mouth daily for the 12 months of study participation.
- norethindrone acetate + placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + a placebo capsule by mouth daily for the 12 months of study participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-75~* Require 1 or 2 level lumbar spinal fusion through posterior or lateral approach~* No history of long term opioid use (daily or almost daily opioid use \> 2 weeks) and not on opiates at time of presentation to clinic~Exclusion Criteria:~* Documented allergy to NSAIDs or Acetaminophen~* History of: Peptic Ulcer Disease, Congestive heart failure, Chronic liver disease, Elevated alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) greater than 1.5 times control, Bleeding disorder, Renal dysfunction (Serum creatinine \> 1.5 mg/dL), Glucocorticoid use within 1 month of surgery~* Current smokers (quite date \< 30 days ago)~* Revision for pseudarthrosis~* Patients who are unable to physically or mentally provide consent to the study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous (IV) Placebo (Type: PLACEBO_COMPARATOR): IV Placebo arm
- IV Ketorolac (Type: EXPERIMENTAL): IV Ketorolac arm
- IV Acetaminophen (Type: EXPERIMENTAL): IV Acetaminophen arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Doxycycline for COPD in HIV-Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Documented HIV infection~2. CD4 cell count greater than 200 cells/mm3~3. HIV RNA less than 400 copies/ml~4. Stable antiretroviral therapy for greater than or equal to 12 weeks~5. Fulfills GOLD definition for COPD (post-bronchodilator FEV1/FVC less than 0.7) and/or has radiographic evidence of emphysema~6. Current or history of smoking with minimum 3 pack-year history~7. ALT and AST less than 3 x upper limit of normal~8. For women of childbearing potential: willingness to use 2 forms of birth control~9. Subjects on therapy for COPD must be on stable therapy for at least 4 weeks~Exclusion Criteria:~1. Pulmonary infection, COPD exacerbation, or acute opportunistic infection within 30 days of entry~2. Conditions associated with increased sedation of bronchoscopy risk, including but not limited to Gold class 3 or 4 COPD, requirement for home oxygen, hypercapneic respiratory failure, poorly controlled hypertension~3. Known allergy/intolerance to doxycycline, atropine, or any local anesthetic~4. Inability to provide informed consent~5. Pregnant or lactating women~6. Men must agree not to attempt to make a woman pregnant or participate in sperm donation during the study and for 6 weeks after discontinuing the drug~7. End stage renal disease~8. Cirrhosis~9. INR greater than 1.4~10. Platelets less than 80,000~11. Any condition including active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements or increase the risk of bronchoscopy~12. Active or planned participation in any other clinical trial or observational study without prior approval from the PI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Doxycycline (Type: ACTIVE_COMPARATOR): 100 mg twice daily (BID orally) x 24 weeks
- Placebo (sugar pill) (Type: PLACEBO_COMPARATOR): 100 mg twice daily (BID orally) x 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PI-88 in Hepatocellular Carcinoma After Hepatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients have voluntarily given written informed consent~* Age ≥ 18 years but ≤ 75 years~* Males or females~* Histological diagnosis of hepatocellular carcinoma~* Curative hepatectomy within the past 4-6 weeks~* ECOG performance status of 0 to 2~* Cardiac functional capacity ≤ to class II (New York Heart Association)~* Patients with adequate renal, hepatic, and haematopoietic function as defined by:~  * Serum creatinine ≤ 2.0 mg/dL~ * Total bilirubin \< 2.5 mg/dL~ * Neutrophil count \> 1.5 x 10\^9/L~ * ALT \< 5 x upper limit of normal (ULN)~ * White blood cell (WBC) count ≥ 3 x 10\^9/L~ * Platelet count ≥ 80 x 10\^9/L~ * Prothrombin time international normalized ratio (PT-INR) ≤ 1.3 (or PT-INR ≤ 1.4 but PT within normal range)~ * Activated partial thromboplastin time (APTT) \< ULN~Exclusion Criteria:~* Patients with history of allergy and/or hypersensitivity to anticoagulants/thrombolytic agents, especially heparin.~* Patients with history of immune mediated thrombocytopenia, thrombotic thrombocytopenic purpura, or other platelet disease~* Patients with previous positive result in a heparin-induced thrombocytopenia (HIT) antibody test.~* Patients with any tumour metastasis.~* Patients with uncontrolled infection or serious infection within the past 4 weeks.~* Patients with myocardial infarction, stroke, or congestive heart failure within the past 3 months.~* Patients with history of inflammatory bowel disease, any other abnormal bleeding tendency, or patients at risk of bleeding due to open wounds or planned surgery.~* Patients with acute or chronic gastrointestinal bleeding within the past 1 year.~* Patients with a history of drug abuse or psychiatric disorder.~* Patients with known HIV infection or AIDS-related illness.~* Patients who received other investigational or anti-neoplastic medication within the past 4 weeks.~* Use of aspirin, aspirin-containing medications, non-steroidal anti-inflammatory drugs (except for COX-2 inhibitors), heparin, low molecular weight heparin, warfarin, anti-platelet drugs, or any other anticoagulant medications 2 weeks prior to or during the study period.~* Women who are pregnant or breast-feeding.~* Women of child-bearing potential who are not using an adequate method of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Untreated Control (Type: NO_INTERVENTION): Untreated control arm
- 160 mg PI-88/Day (Type: EXPERIMENTAL): PI-88 160 mg/day SC injection
- 250 mg PI-88/Day (Type: EXPERIMENTAL): PI-88 250 mg/day SC injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Myocardial rest/regadenoson stress perfusion PET study within 60 days~* Normal rest LVEF (greater than or equal to 50%)~* No change in symptoms or treatment between the PET and the MRI study~* Willing to consent to the study~* Male or female who is either post-menopausal, surgically sterile, or if has a childbearing potential, a negative pregnancy test within 2 days prior to the MRI study.~Exclusion Criteria:~* Renal dysfunction (estimated glomerular filtration rate \< 60 mL/min/1.73m2) within 6 months~* Metallic implants, pacemaker, blood vessel clip (contra-indicated for MRI)~* Patient size exceeds MRI bore/table limits: (Max body diameter \> 60 cm, weight \> 136 kg)~* History of gadolinium contrast allergy or intolerance~* Second or third degree AV block~* Sinus node dysfunction~* Acute myocardial infarction (past 3 months)~* Actively wheezing or with acute asthma or bronchospastic attacks requiring changes in therapy within the past 30 days~* Patients that have experienced a previous hypersensitivity reaction thought to be related to regadenoson

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Regadenoson (Type: OTHER): Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile~* Chronic hepatitis C, genotype 1a-infection (HCV RNA level greater than or equal to 10,000 IU/mL at screening)~* Subject has never received antiviral treatment for hepatitis C infection~* No evidence of liver cirrhosis~Exclusion Criteria:~* Significant liver disease with any cause other than HCV as the primary cause~* Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody~* Positive screen for drugs or alcohol~* Significant sensitivity to any drug~* Use of contraindicated medications within 2 weeks of dosing~* Abnormal laboratory tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 and ABT-333, Plus RBV (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
- ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>=70 years of age~* Non-small cell lung cancer~* Naive to prior chemotherapy or specific immunotherapy~* Presence of at least 1 measurable lesion~Exclusion Criteria:~* Active non-controlled infection or disease~* CNS metastases~* Any other malignancies (other than adequately treated basal cell cancer of skin, or in situ cancer of the cervix)

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Red Cell Transfusion Goals in Patients With Acute Leukemias

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute leukemia patients (AML, ALL, APL, treatment-related myeloid neoplasm, high grade MDS)~* Admitted with plans for inpatient myelosuppressive chemotherapy (with standard of care or protocol regimens)~Exclusion Criteria:~* Age less than 18 years~* Acute coronary syndrome as defined by active chest pain, dynamic ECG changes, troponin greater than 2.5~* Active blood loss~* Receiving erythropoietin stimulating agents prior to admission~* Chronic Renal Failure in Renal Replacement Therapy~* Documented wish against transfusion for personal or religious beliefs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low transfusion threshold (Type: EXPERIMENTAL): Patients receive red blood cell transfusions with a transfusion threshold of 7 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.
- High transfusion threshold (Type: ACTIVE_COMPARATOR): Patients receive red blood cell transfusions with a transfusion threshold of 8 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel in Locally Advanced Gastric Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven gastric adenocarcinoma diagnosis~* Selected Stage IIB (T3N0M0), Stage IIIA (T2aN2M0, T2bN2M0, T3N1M0, T4N0M0), Stage IIIB (T3N2M0) and selected Stage IV (all T4 , NM0, all TN3M0's). Clinical staging performed with endoscopic ultrasound and CT. Laparotomy or laparoscopy is preferred to determine resectability and peritoneal involvement.~* ECOG performance status between 0 and 2~* Acceptable hematological profile :~  * WBC (White Blood Cell) count ≥4000/mm3~ * Platelet count ≥100 000 mm3~ * Hemoglobin ≥9 g/100 mL (if lower, may be included following transfusion)~* Adequate renal function~  * Serum creatinine \<1.2 mg/dl or calculated creatinine clearance in 24-hours urine \>60 mL/min.~* Adequate hepatic function~  * Bilirubin \< UNL~ * Transaminases (ALT, AST) \<2.5 x UNL~ * Alcaline phosphatase \<2.5 x UNL~* Adequate pulmonary function~* Adequate cardiac function~* No prior chemotherapy for gastric cancer~Exclusion Criteria:~* Other histological types of gastric cancer (leiomyosarcoma, lymphoma) than adenocarcinoma~* Pregnant or lactating patients~* Patients with brain, bone or other metastases; peritoneal involvement~* Other serious underlying medical conditions which could impair the ability of the patient to participate in the study (congestive heart failure, serious arrhythmia, uncontrolled diabetes mellitus, serious neuropathy), history of myocardial infarction within 6 months prior to study entry~* Previous or other current malignancies, with the exception of carcinoma of the cervix uteri or breast cancer or basal cell skin cancer and a disease-free period shorter than 5 years~* Active infection and other serious disease~* Any other experimental drugs within a 4-week period prior to the study~* Contraindications for the use of any study drug (e.g. history of hypersensitivity to the contents of the study drugs)~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Docetaxel/Cisplatin/Fluorouracil (DCF) (Type: EXPERIMENTAL): DCF combination for three 21-day cycles unless a disease progression is observed at the tumor assessment scheduled after the second cycle or due to patient intolerability

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete